85 results about "Thrombopoiesis" patented technology

Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and / or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia.

The invention relates to methods for regulating hematopoiesis using CpG containing oligonucleotides. In particular, the invention relates to methods of treating thrombopoiesis and anemia by regulating hematopoiesis. The invention also relates to methods of regulating immune system remodeling by administering CpG oligonucleotides to control hematopoiesis.

The present invention provides a method for expanding an endothelial progenitor cell in vitro. More particularly, the present invention provides a method for culturing a hemangioblast comprising incubating a hemangioblast in a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 and thrombopoietin, and a vascular endothelial cell produced by the method; and a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 and thrombopoietin, and a kit for the preparation of the serum-free culture medium and the like.

The present inventors used antibody engineering techniques to prepare functional antibodies that correspond to individual mutations in causative genes of diseases, and discovered that such antibodies enable the treatment of the diseases. Specifically, the inventors succeeded in preparing ligands, particularly minibodies, which have agonistic activity to receptors that have almost completely lost responsiveness to their natural ligands because of gene mutations (for example, a thrombopoietin (TPO) receptor whose reactivity to TPO has been markedly impaired), and which can transduce signals by interacting with these mutant receptors at levels comparable to normal.

Disclosed herein are novel diazenyl pyrazole compounds and related compounds. Also disclosed herein are methods of using these compounds for the treatment of diseases and conditions associated with modulating a thrombopoietin activity.

The invention relates to kudzuvine flower health tea as restoring tea of She nationality, which is prepared from kudzuvine flowers, kudzu roots, hovenia dulcis thunb, fiveleaf gynostemma herb, ginseng leaves and fresh tea leaves. The kudzuvine flower health tea is similar to a tea in the characters, a storage mode and a drinking method, can be drunk once being brewed with water, is convenient to drink when a person drinks wines and after the person drinks the wines, has the effects of preventing drunkenness and helping dispeling the effects of alcohol after drunkenness, also has various health effects of preventing and auxiliarily treating hypertension, hyperlipidemia, hyperglycemia, arteriosclerosis, thrombopoiesis, cardiovascular diseases, migraine, inflammation, gastrointestinal ulcer,tumors, cancers, the toxic or side effects of hormone medicines and the like, can calm nerves, nourish the nature, defer senility, improve mental activities, enhance the cerebral functions, activate human normal cells, inhibit fatness, strengthen the spleen and the stomach, relieve the fatigue, fulfill the functions of calming, hypnosis and stress resistance, strengthen the immune function of a human body, moisten the intestines to have remarkable effects on constipation, and also has certain actions of blacking hairs and beautifying. The kudzuvine flower health tea has the advantages of simple and complete compositions, moderate actions, no toxic or side effects and various health effects; the characters of the selected raw materials accord with the conventional acknowledgement of peopleto tea; and the kudzuvine flower health tea tastes fragrant after being brewed with water.

The present invention provides methods for the identification of CD4+ T-cell epitopes in the sequences of various proteins, namely, human cytokines and cytokine receptors, as well as the production of peptides which when incorporated into the protein sequence, are no longer capable of initiating the CD4+ T-cell response. In some embodiments, the present invention provides means and compositions suitable for reducing the immunogenicity of cytokines and cytokines receptors such as interferon-β, soluble tumor necrosis factor receptor-1, erythropoietin, and thrombopoietin.

An immune enhancing blood platelet builder that increases the survival rate of the patient against the duration of the dengue fever virus in the body.

The invention discloses preparation and application of a dimerized thrombopoietin (TPO) mimic peptide TMP diad-human serum albumin fusion protein. The fusion protein contains an HAS and two TPO mimic peptides which are connected through a linkage oligopeptide and a dimerization domain so as to ensure the fusion protein is dimerized correctly when expression. The two TPO mimic peptides can be connected with N terminal or C terminal of HAS. The dimerized HAS protein carrier and the TPO mimic peptide fusion protein provided by the invention have a significant activity of promoting thrombopoiesis in vivo and can be applied in preparation of drugs for treating primary and secondary thrombocytopenia diseases.

The invention discloses a medicine for treating and preventing ischemic cardiovascular and cerebrovascular diseases, which belongs to the field of traditional Chinese medicine and is composed of the following bulk pharmaceutical chemicals by weight: 3-5 parts of Astragalus mongholicus, 3-5 parts of suncured ginseng, 2-10 parts of rheum officinale, 3-5 parts of leeches, 3-5 parts of radix notoginseng, 2-3 parts of Ligusticum wallichii, 3-5 parts of radix salviae miltiorrhizae, 2-10 parts of the root of kudzu vine, 2-3 parts of corydalis tuber and 1-2 parts of dragon's blood. By proportioning the bulk pharmaceutical chemicals, the medicine has the functions of tonifying qi, activating blood circulation and removing stasis, resisting atherosclerosis and resisting thrombopoiesis. The medicine has the advantages of being used in treating, primary prevention, secondary prevention and tertiary prevention of ischemic cardiovascular and cerebrovascular diseases and achieving good clinical effects. Condition of patients is stable, and the diseases can no longer occur, heart and brain functions are obviously improved, lift quality is obviously improved, and patients with light illness can return back to work.

The invention discloses a method for renaturing and purifying novel thrombopoietin mimetic peptide, the method comprises the following steps: performing a high density fermentation to escherichia coli engineering bacteria containing thrombopoietin mimetic peptide, carrying out an ultrasonication to thalline, urea cracking, renaturing, regulating the pH value, combining and purifying through Protein-AMabselectSuRe chromatography, SPSepharoseH.P chromatography and Sephacry1S-200 molecular sieve chromatography, and preparing thrombopoietin mimetic peptide protein which conforms to the Chinese pharmacopoeia specification. The beneficial effects of the present invention have high renaturation rate, reasonable purifying process combination, simplified operation program, high yield and low production cost, and the method provides the possibility for the large scale production of the thrombopoietin mimetic peptide.

The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human thrombopoietin (TPO) to result in TPO proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

The present invention relates to a synthetic variable region of an immunoglobin construct which contains in at least one of its CDRs a sequence of thrombopoietin, e.g., IEGPTLRQWLAARA or its derivatives. This construct can efficiently bind and activate a thrombopoientin receptor (MPL) leading to stimulation of proliferation, growth or differentiation or modulation of apoptosis of hematopoietic cells, especially platelet progenitor cells. The invention further relates to the use of the synthebody to treat hematopoietic or immune disorders, and particularly thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions.

The invention provides a traditional Chinese medicine preparation for treating immune thrombocytopenia (ITP) and a preparation method thereof. The traditional Chinese medicine preparation comprises the following components in parts by weight: 1 part of selaginella tamariscina, 1-2 parts of acanthopanax, 1-2 parts of morinda officinalis, 1-2 parts of dandelion, 1-2 parts of pseudo-ginseng, 1-2 parts of spatholobus stem, 1-2 parts of white peony root, 1-2 parts of angelica, 1-2 parts of bighead atractylodes rhizome, 1-2 parts of red sage root, 1-2 parts of radix rehmanniae, 1-2 parts of radix astragali, 1-2 parts of dangshen, 1-2 parts of agrimony and 1-2 parts of dodder. From the perspective of modern pharmacological research, the medicines contained by the traditional Chinese medicine preparation of the invention have the effects of regulating immunity, reducing platelet destruction, promoting thrombopoiesis, reducing capillary permeability and the like, thereby achieving the purpose of treating ITP. The medicines are compatible, the formula is simple and complete and hits the pathogenesis, and the medicines play the effects of removing pathogenic heat from blood, removing blood stasis, arresting bleeding, and reinforcing the spleen and kidney, thereby reducing hemorrhage of patients with ITP and alleviating various clinical symptoms.

The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakary-ocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.

The present invention relates to mainly one system of efficient culturing and directive inducing stem cell differentiation for culturing and proliferating megakaryocyte. The system has umbilical cord blood and marrow stem cell as seed cell, and the serum-free culture medium comprising TPO, IL-11 and heparin as the main component for megakaryocyte proliferation. The megakaryocyte preparation prepared based on the present invention contains great amount of macronucleus ancestral cells and mature megakaryocyte as well as CD34+ cells, and has the functions of treating thrombocytopenia and improving the blood-forming function after stem cell transplantation. The present invention provides novel efficient cell treating preparation for various thrombocytopenia and hemocyitopenia.

Disclosed herein is a stent which is inserted into a blood vessel of a patient who has to undergo hemodialysis. The stent includes a wire frame which has a hollow cylindrical structure, and a window which is formed in a partial portion of a circumferential surface of the wire frame. The window has no wire therein. According to one aspect of the invention, the stent may further comprise a graft which covers the stent. Such a structure allows puncturing using a needle and inserting the needle into the window of the stent inside the blood vessel of the patient who has to periodically undergo hemodialysis, so as to makes it possible for hemodialysis to be reliably conducted for the patient who receives the treatment of inserting the covered stent due to arterial aneurysm. In this way, the present invention can solve problems not only of deformation of the covered stent which occurs when a hemodialysis needle is inserted into the stent, but also of patient discomfort when having skin punctured, high cost, thrombopoiesis, a risk of recurrence, etc.

The invention belongs to the field of medical technology and relates to a kudzu-vine root daidzein-7, 4'-dioxo acetic acid compound and a preparation method thereof; the compound has the following formula, wherein R1 and R2 can be the same of different and are chosen from H, metal ions, organic cations, basic amino acid cations, C1-C10 alkyl group independently; R3 and R4 can be the same or different and are independently chosen from H or C1-C10 alkyl group; the kudzu-vine root daidzein-7, 4'-dioxo acetic acid compound, and a carrier or excipient which can be acceptable medically are combined to form medicine composite; the compound and the medicine composite has the advantages of cerebral ischemia resistance, oxygen-poor resistance, myocardial ischemia resistance, antagonistic dysmnesia resistance, platelet aggregation resistance and thrombopoiesis resistance and protecting rat cortical neuron damage caused by oxygen deficit.

The invention discloses argatroban injection for resisting thrombus. The argatroban injection contains 0.5mg / mL of argatroban, 0.1-0.4mg / mL of nitroglycerin and 30-80mg / mL of D-sorbierite. The argatroban injection is good in stability, has obvious effect in resisting thrombopoiesis, simultaneously reduces bleeding danger of the argatroban and obviously reduces the bleeding rate.

The invention discloses argatroban injection for resisting thrombus. The argatroban injection contains 0.5mg / mL of argatroban, 0.1-0.4mg / mL of nitroglycerin and 30-80mg / mL of D-sorbierite. The argatroban injection is good in stability, has obvious effect in resisting thrombopoiesis, simultaneously reduces bleeding danger of the argatroban and obviously reduces the bleeding rate.

The invention relates to N-unsaturated fatty acid acylated chitosan oligosaccharide and preparation and application thereof, which is a mixing component with the molecular weight of 800-15000Da. Degree of deacetylation of the mixing component is 50%-100%, degree of substitution of the N-unsaturated fatty acid acylated is 30-100%, the structure of the composition is shown in the description, wherein R is the N-unsaturated fatty acid acylated acyl group, hydrogen or CH3CO- with the carbon chain length of 12-22, and n is an integral between 0 and 30. The first glass N-unsaturated fatty acid acylated chitosan oligosaccharide can resist oxidant, delay senility, restrain tumour, resist inflammatory, reduce blood press, avoid thrombopoiesis, improve diabetes mellitus, regulate blood sugar level, resist atherosclerosis, promote plant grow and induce activity such as plant antiviral, and the first glass N-unsaturated fatty acid acylated chitosan oligosaccharide can serve as important raw materials of medicaments, health foods, cosmetics and biopesticide.

The invention discloses an analysis method for evaluating in-vitro activity of a thrombopoietin (TPO) receptor stimulant. According to the method, the binding activity of a sample and a TPO receptor and the activity of the thrombopoietin are reflected by evaluating the proliferation-promoting development capacity of the sample on cells. By adopting the method, on one hand, the problem that BaF3-hMpl cell system in the prior art is great in establishing difficulty, great in time consumption and instable in detection result can be solved; on the other hand, the problems that by adopting a suspension cell MTT method, the color developing time is long, an insoluble formazan product is generated, the result reproductivity is poor and the accuracy is low can be solved; meanwhile, a four-parameter data processing method which is better than survival rate evaluation indexes is adopted, so that the activity value of the sample can be directly defined.

The invention belongs to a method for preparing sodium quercetin-7-sulfate and application of the sodium quercetin-7-sulfate to the preparation of medicaments and health-care products for resisting thrombus. The sodium quercetin-7-sulfate is applied to the preparation of medicaments and health-care products for resisting platelet aggregation and the thrombus or is used as components of the medicaments and the health-care products for resisting the platelet aggregation and the thrombus or is used as the precursor of the medicaments for resisting the platelet aggregation and the thrombus to be transformed. The sodium quercetin-7-sulfate which is subjected to artificial semisynthesis can inhibit the platelet aggregation obviously and prevent thrombopoiesis, and has good effects of resisting the platelet aggregation and the thrombopoiesis.

The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.

The invention belongs to the field of genetic engineering pharmacy, relates to a fusion protein of thrombopoietin and a preparation method and an application thereof, in particular to the fusion protein of a human serum albumin (HSA) and a yeast-preferred codon-encoded thrombopoietin mimetic peptide (TMP) diad and the preparation method and the application thereof. The fusion protein comprises theHSA molecule and the yeast-preferred codon-encoded TMP diad, the fusion protein can be stably expressed at a high level in yeast, and can be applied to industrial production; at the same time, the fusion protein has a characteristic of promoting thrombopoiesis significantly, has a long half-life in the human body, and can be used for preparing a medicine for treating various diseases such as primary or secondary thrombocytopenia.

The invention provides an oligopeptide R-G-S(p)-L-P capable of influencing platelet function or trim / derivate thereof and application of the oligopeptide R-G-S(p)-L-P or trim / derivate thereof in preventing and / or treating arterial thrombus disease and / or related disease interacted by platelet GPIbalpha and ABP. The platelet treated by the oligopeptide R-G-S(p)-L-P or trim / derivate thereof can effectively inhibit adhesion function of the platelet including ristomycin induced platelet aggregation function without influencing platelet aggregation function including ADP induced platelet aggregation function, thus inhibiting thrombopoiesis while basically maintaining the integrity of platelet functional status. The invention can be directly used for research and development of clinical anti-thrombus medicine.